Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
SYDNEY, AUSTRALIA, Dec. 16, 2021 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a biotechnology company developing novel LAG-3 related immunotherapy...
-
SYDNEY, AUSTRALIA, Dec. 02, 2021 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a biotechnology company developing novel LAG-3 related immunotherapy...
-
Enrolled and dosed last patient in the expansion stage of Part A (1st line non-small cell lung cancer (NSCLC)) needed to complete recruitment into all cohorts of the TACTI-002 studyInterim data from...
-
AIPAC poster presentation includes new data and graphs showing: Very encouraging Overall Survival (OS) data from the abstract published on 9 November 2021, including statistically significant benefit...
-
SYDNEY, AUSTRALIA, Nov. 15, 2021 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a biotechnology company developing novel LAG-3 related immunotherapy...
-
Data from Phase IIb AIPAC, including final Overall Survival data, reported in a separate announcementEncouraging Objective Response Rate (ORR) of 29.7% (11/37), including 5 Complete Responses in 2nd...
-
Final Overall Survival (OS) data supports Phase III clinical development of efti in combination with paclitaxel in metastatic breast cancerOS benefit trend in total population, with median survival...
-
SYDNEY, AUSTRALIA, Nov. 02, 2021 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a biotechnology company developing novel LAG-3 related immunotherapy...
-
Positive feedback for the general clinical development program including the planned registrational Phase III trial in metastatic breast cancer (MBC)Other regulatory engagement ongoing, including with...
-
Received competent authority and institutional review board approvals for TACTI-003 Phase IIb trialEnrolled first patient in INSIGHT-003 study in patients with various solid tumoursPreparations...